Collegium Pharma (COLL) Provides 2025 Financial Guidance and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq futures take lead after Nvidia forecast refuels AI trade
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of Hormuz reopening
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Collegium Provides 2025 Financial Guidance and Business Update
January 8, 2025 8:00 AM ESTProduct Revenues, Net Expected in the Range of $735 Million to $750 Million
Jornay PM® Net Revenue Expected to be in Excess of $135 Million
Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million
Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million
STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update.
In 2024, we executed on our priorities of maximizing the... More
